Dr. Ian Smith, as the newly appointed chief medical officer, will assume responsibility for leading Artios’s overall preclinical and clinical development strategy, regulatory, and medical activities, and will work in tandem with and report directly to Niall Martin, chief executive officer, and join the company’s executive leadership team.

Dr. Smith joins Artios from Eli Lilly where, as a Senior Medical Director he was responsible for the successful clinical development and worldwide regulatory approval of key breakthrough oncology medicines in multiple indications. Prior to Eli Lilly, Ian spent eight years at AstraZeneca where he was involved in the early clinical development of several oncology compounds, and led a cross portfolio team for breast cancer, and as Global Clinical Team Leader was responsible for the development of lead oncology drugs within the Global Medicines Development Division.

Dr. Smith commented: “The Artios pipeline offers one of the most exciting approaches to cancer treatment.  I look forward to working with the rest of the management team and world-leading Clinical Advisory Board, to progress our pipeline of DDR therapies, particularly Polθ which has multiple opportunities to treat some difficult cancers, providing new treatment options for patients.”